February 1, 2021 11:14 AM EST
News Briefing

Con­cert crushed on PhII schiz­o­phre­nia flop; Am­gen's so­tora­sib gets BTD in Chi­na

Max Gelman

Senior Editor

Nicole DeFeudis

Editor

Con­cert Phar­ma­ceu­ti­cals stock tanked near­ly 40% on Mon­day morn­ing when a ma­jor Phase II flop left the biotech no choice but to ax its schiz­o­phre­nia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

A service from the Financial Times